Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170)

AIDS

Volumn 26, Issue 1, 2012, Pages 1-9

  McLinden, Robert J ^a,c   Paris, Robert M ^b   Polonis, Victoria R ^c   Close, Nicole C ^d   Su, Zhaohui ^e   Shikuma, Cecilia M ^a   Margolis, David M ^f   Kim, Jerome H ^c  

^a UNIVERSITY OF HAWAII   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d EmpiriStat Inc   (United States)

^e HARVARD UNIVERSITY   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

CD4 +; HIV; neutralizing antibodies; T cells HAART; viral load

Indexed keywords

NEUTRALIZING ANTIBODY;

ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS LOAD;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; NEUTRALIZATION TESTS; PROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; WITHHOLDING TREATMENT;

EID: 82455171866     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834d606e     Document Type: Article

References (67)

1. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4R T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116.
2. Pontesilli O, Kerkhof-Garde S, Pakker NG, Notermans DW, Roos MT, Klein MR, et al. Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection. Immunol Lett 1999; 66:213-217.
3. Angel JB, Kumar A, Parato K, Filion LG, Diaz-Mitoma F, Daftarian P, et al. Improvement in cell-mediated immune function during potent antihuman immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998; 177:898-904.
4. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351:1682-1686.
5. Sarmati L, d'Ettorre G, Nicastri E, Ercoli L, Uccella I, Massetti P, et al. Neutralizing antibodies against autologous human immunodeficiency virus type1 isolates in patients with increasingCD4 cell counts despite incomplete virus suppression during antiretroviral treatment. Clin Diagn Lab Immunol 2001; 8:822-824.
6. Kim JH, Mascola JR, Ratto-Kim S, VanCott TC, Loomis-Price L, Cox JH, et al. Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection. AIDS Res Hum Retroviruses 2001; 17:1021-1034.
7. Birk M, Aleman S, Visco-Comandini U, Sonnerborg A. Proviral HIV-1 dynamics and evolution in patients receiving efficient long-term antiretroviral combination therapy. HIV Med 2000; 1:205-211.
8. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviraltherapy- related lipodystrophy. Lancet 1999; 354:1112-1115.
9. Haddow LJ, Wood CW, Ainsworth JG. Discontinuation of nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related metabolic toxicity. Int J STD AIDS 2007; 18:343-346.
10. Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Zayat MK, Marfil S, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 2000; 14:397-403.
11. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
12. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-526.
13. Boschi A, Tinelli C, Ortolani P, Moscatelli G, Morigi G, Arlotti M. CD4Rcell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy. AIDS 2004; 18:2381-2389.
14. Skiest DJ, Su Z, Havlir DV, Robertson KR, Coombs RW, Cain P, et al. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis 2007; 195:1426-1436.
15. Volberding P, Demeter L, Bosch RJ, Aga E, Pettinelli C, Hirsch M, et al. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS 2009; 23:1987-1995.
16. Lori F, Foli A, Maserati R, Seminari E, Xu J, Whitman L, et al. Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses. HIV Clin Trials 2002; 3:115-124.
17. Binley JM, Trkola A, Ketas T, Schiller D, Clas B, Little S, et al. The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182:945-949.
18. Ortiz GM, Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999; 104:R13-R18.
19. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010; 329:811-817.
20. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285-289.
21. Montefiori DC, Hill TS, Vo HT, Walker BD, Rosenberg ES. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol 2001; 75:10200-10207.
22. Vahey MT, Wang Z, Su Z, Nau ME, Krambrink A, Skiest DJ, et al. CD4R T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway. AIDS Res Hum Retroviruses 2008; 24:1047-1066.
23. Swanson P, Devare SG, Hackett J Jr. Full-length sequence analysis of HIV-1 isolate CM237: a CRF01-AE/B intersubtype recombinant from Thailand. AIDS Res Hum Retroviruses 2003;19:707-712.
24. Hioe CE, Xu S, Chigurupati P, Burda S, Williams C, Gorny MK, et al. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int Immunol 1997; 9:1281-1290.
25. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory- adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996; 173:340-348.
26. Mascola JR, Louwagie J, McCutchan FE, Fischer CL, Hegerich PA, Wagner KF, et al. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J Infect Dis 1994; 169:48-54.
27. Collman R, Balliet JW, Gregory SA, Friedman H, Kolson DL, Nathanson N, et al. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol 1992; 66:7517-7521.
28. Mascola JR. Neutralization of HIV-1 infection of human peripheral blood mononuclear cells (PBMC): antibody dilution method. In: Michael NL, Kim JH, editors. HIV protocols. Totowa: Humana Press; 1999. pp. 309-315.
29. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121-130.
30. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44:1049-1060.
31. Jacobson JM, Pat Bucy R, Spritzler J, Saag MS, Eron JJ Jr, Coombs RW, et al. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452; promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis 2006; 194:623-632.
32. Fisher RA. The correlation between relatives on the supposition of Mendelian inheritance. Transcripts of the Royal Society of Edinburgh 1918; 52:399-433.
33. Weisberg S. Applied linear regression, 3rd ed. Hoboken: John Wiley and Sons, Inc.; 2005.
34. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virusspecific CD8R cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-6110.
35. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-4655.
36. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4R T cell responses associated with control of viremia. Science 1997; 278:1447-1450.
37. Ariyoshi K, Harwood E, Chiengsong-Popov R, Weber J. Is clearance of HIV-1 viraemia at seroconversion mediated by neutralising antibodies? Lancet 1992; 340:1257-1258.
38. Pellegrin I, Legrand E, Neau D, Bonot P, Masquelier B, Pellegrin JL, et al. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11:438-447.
39. Moore JP, Ho DD. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol 1993; 67:863-875.
40. Poignard P, Sabbe R, Picchio GR, Wang M, Gulizia RJ, Katinger H, et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999; 10:431-438.
41. Carotenuto P, Looij D, Keldermans L, de Wolf F, Goudsmit J. Neutralizing antibodies are positively associated with CD4R T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 1998; 12:1591-1600.
42. Harrer T, Harrer E, Kalams SA, Elbeik T, Staprans SI, Feinberg MB, et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 1996; 12:585-592.
43. Lewis J, Balfe P, Arnold C, Kaye S, Tedder RS, McKeating JA. Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. J Virol 1998; 72:8943-8951.
44. Loomis-Price LD, Cox JH, Mascola JR, VanCott TC, Michael NL, Fouts TR, et al. Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. J Infect Dis 1998; 178:1306-1316.
45. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson EE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by pasive infusion of neutralizing antibodies. Nat Med 2000; 6:207-210.
46. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng- Mayer C, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75:8340-8347.
47. Nishimura Y, Igarashi T, Haigwood N, Sadjadpour R, Plishka RJ, Buckler-White A, et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 2002; 76:2123-2130.
48. Trkola A, Kuster H, Rusert P, von Wyl V, Leemann C, Weber R, et al. In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J Virol 2008; 82:1591-1599.
49. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009; 83:7337-7348.
50. Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, Grise H, et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006; 80:2515-2528.
51. Robinson WE. Mechanism for complement-mediated, antibody- dependent enhancement of human immunodeficiency virus type 1 infection in MT2 cells is enhanced entry through CD4, CD21, and CXCR4 chemokine receptors. Viral Immunol 2006; 19:434-447.
52. Huerta L, Gomez-Icazbalceta G, Soto-Ramirez L, Viveros-Rogel M, Rodriguez R, Fuentes L, et al. Human immunodeficiency virus 1 (HIV-1) envelope-dependent cell-cell fusion modulation by HIV-positive sera is related to disease progression. J Gen Virol 2005; 86:1961-1966.
53. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-104.
54. Szabo J, Prohaszka Z, Toth FD, Gyuris A, Segesdi J, Banhegyi D, et al. Strong correlation between the complement-mediated antibody-dependent enhancement of HIV-1 infection and plasma viral load. AIDS 1999; 13:1841-1849.
55. Takeda A, Robinson JE, Ho DD, Debouck C, Haigwood NL, Ennis FA. Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120. J Clin Invest 1992; 89:1952-1957.
56. Connor RI, Dinces NB, Howell AL, Romet-Lemonne JL, Pasquali JL, Fanger MW. Fc receptors for IgG (Fc gamma Rs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including the Fc gamma R. Proc Natl Acad Sci U S A 1991; 88:9593-9597.
57. Subbramanian RA, Xu J, Toma E, Morisset R, Cohen EA, Menezes J, et al. Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients. J Clin Microbiol 2002; 40:2141-2146.
58. Stewart SA, Poon B, Jowett JB, Chen IS. Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol 1997; 71:5579-5592.
59. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1995; 1:129-134.
60. Trkola A, Kuster H, Leemann C, Oxenius A, Fagard C, Furrer H, et al. Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. Blood 2004; 104:1784-1792.
61. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008; 197:563-571.
62. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-312.
63. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, Paxinos E, et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A 2005; 102:18514-18519.
64. Tomaras GD, Haynes BF. HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr Opin HIV AIDS 2009; 4:373-379.
65. Markowitz M, Vesanen M, Tenner-Racz K, Cao Y, Binley JM, Talal A, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999; 179:527-537.
66. Morris MK, Katzenstein DA, Israelski D, Zolopa A, Hendry RM, Hanson CV. Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 2001; 28:405-415.
67. Ogg GS, Jin X, Bonhoeffer S, Moss P, Nowak MA, Monard S, et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999; 73:797-800.